Gedeon Richter Plc. and Forest Laboratories, Inc. Announce Positive Phase IIb Topline Results for Cariprazine for the Treatment of Bipolar Depression

Gedeon Richter Plc. and Forest Laboratories, Inc. (NYSE: FRX) announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression.